BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19779314)

  • 1. Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.
    Vogel VG
    Menopause; 2009; 16(6):1079-82. PubMed ID: 19779314
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SERM-therapy in postmenopause. Protection of bone and breast].
    MMW Fortschr Med; 2001 Jan; 143(4):47. PubMed ID: 11219288
    [No Abstract]   [Full Text] [Related]  

  • 4. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 6. [CORE study].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():294-8. PubMed ID: 18161121
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].
    Kreienberg R; Kafka A
    MMW Fortschr Med; 2003 Jun; 145(24):32-3. PubMed ID: 12866296
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ; Kimler BF
    J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Yalcin B; Buyukcelik A; Yalcin S; Utkan G; Doruk H; Dogan M; Altan M
    J Natl Cancer Inst; 2005 Apr; 97(7):542; author reply 542-3. PubMed ID: 15812082
    [No Abstract]   [Full Text] [Related]  

  • 17. [Selective estrogen receptor modulators (SERM's) in postmenopausal women].
    Kleiverda G
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2446-7. PubMed ID: 10608980
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise of raloxifene and the fall of invasive breast cancer.
    Jordan VC
    J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.